{"entity":{"id":"corvus-pharmaceuticals","kind":"company","name":"Corvus Pharmaceuticals","aka":["Corvus Pharmaceuticals, Inc.","NASDAQ:CRVS"],"tldr":"Corvus Pharmaceuticals is a Californian biotech whose oral ITK inhibitor soquelitinib rebalances T cells, with a registrational trial in relapsed T-cell lymphoma and studies in atopic dermatitis.","summary":"Corvus Pharmaceuticals develops soquelitinib (CPI-818), a selective covalent inhibitor of interleukin-2-inducible T-cell kinase (ITK) that blocks malignant T cells and steers helper T cells towards a Th1 profile. It is in a registrational phase 3 trial in relapsed peripheral T-cell lymphoma and in phase 1 trials in atopic dermatitis. The company also developed the adenosine A2A antagonist ciforadenant and the CD73 antibody mupadolimab.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.corvuspharma.com/"}],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["soquelitinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Burlingame, California","country":"US","companyType":"biotech","website":"https://www.corvuspharma.com/","ticker":"NASDAQ:CRVS","founded":2014,"stage":"public","investors":[],"funding":[]},"route":"/companies/corvus-pharmaceuticals/","neighbours":{"drug":[{"id":"soquelitinib","kind":"drug","name":"Soquelitinib","route":"/drugs/soquelitinib/"}]}}